The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | Main goals for treating patients with AL amyloidosis: achieving complete hematologic response
Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, briefly discusses the main goals for treating patients with light chain (AL) amyloidosis, emphasizing the importance of achieving a complete hematologic response (CHR). Prof. Sanchorawala also comments on the value of measurable residual disease (MRD) assessment in these patients. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
